BioVie (BIVI) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
15 Jan, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key executives attending virtually.
Independent public accountants and outside securities counsel were present.
Secretary appointed to record minutes and report on formal meeting steps.
Corporate governance
Record date for voting set as September 30, 2024, with 7,956,660 shares outstanding.
Notice of meeting, proxy statement, and annual report mailed to shareholders on October 9, 2024.
Each share entitled to one vote; quorum confirmed with 60.8% of shares represented.
Board and executive committee updates
Six directors nominated and elected for a one-year term: Jim Lang, Cuong Do, Michael Sherman, Richard Berman, Robert Hariri, and Sigmund Rogich.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioVie
- Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVI
Status update4 Mar 2026 - Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVI
Q2 20266 Feb 2026 - Directors elected, auditor ratified, and equity plan amendment approved by strong majority.BIVI
AGM 20253 Feb 2026 - Key clinical trials advance with strong cash runway and major data readouts expected by mid-2026.BIVI
Investor Update29 Dec 2025 - Shareholders will vote on director elections, auditor ratification, say-on-pay, and a major equity plan increase.BIVI
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and expanding the equity plan.BIVI
Proxy Filing2 Dec 2025 - Virtual annual meeting to vote on directors, auditor, pay, and expanded equity plan.BIVI
Proxy Filing2 Dec 2025 - Supplement details updated executive and director compensation, equity awards, and related party transactions.BIVI
Proxy Filing2 Dec 2025 - Shareholders to vote on a reverse stock split and adjournment authority to support Nasdaq compliance.BIVI
Proxy Filing2 Dec 2025